The study aims to characterize clinical features and outcomes of NSCLC patients with the EML4-ALK mutation.
Analysis of clinical features in patients with EML4-ALK mutation in NSCLC.
Assessment of treatment outcomes compared to those not harboring the mutation.
Patients with EML4-ALK do not benefit from EGFR TKIs, indicating ineffective treatment.
Recommendation for directing these patients toward trials of ALK-targeted therapies.
Abstract
EML4-ALK defines a molecular subset of NSCLC with distinct clinical characteristics. Patients who harbor this mutation do not benefit from EGFR TKIs and should be directed to trials of ALK-targeted agents.